Lv52
980 积分 2024-07-09 加入
Ponsegromab for the Treatment of Cancer Cachexia
16天前
已完结
OA-27 Fifteen-Month Follow-Up from a Pivotal Trial of GR1803 in Patients with Relapsed/Refractory Multiple Myeloma
1个月前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
1个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
3个月前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
3个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
5个月前
已完结
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer
6个月前
已完结
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer
7个月前
已完结
[Expert consensus on the management practice of CD19 CAR-T cell therapy for B-cell lymphoma in China (2025 edition)]
7个月前
已完结
Five‐Year Follow‐Up: Tandem CD19 / CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non‐Hodgkin Lymphoma
7个月前
已完结